Reaction Biology Announces Closing of Growth Investment from Cobepa and Chief Executive Officer Transition

/PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry- leading provider of drug discovery services, today announced the closing of a...

Related Keywords

Germany ,New York ,United States ,Munich ,Bayern ,Brussels ,Bruxelles Capitale ,Belgium ,Matthew Oristano ,Piper Sandler ,Cobepa Sa ,Lindsay Rocco ,Peter Connolly ,Johnh Johnson ,Strongbridge Biopharma ,Edward Sohn ,John Johnson ,Eli Lilly Company Worldwide Oncology Unit ,William Blair Co ,Xeris Biopharma Holdings Inc ,Reaction Biology For The Company ,Elixir Health Public Relations ,Xeris Biopharma Holdings ,Johnson ,Company Group ,White Case ,Imclone Systems Inc ,Chief Executive Officer ,Board Director ,Reaction Biology ,Reaction Biology Well Positioned ,Expand Upon Global Drug Discovery Capabilities ,Managing Director ,Cobepa North ,Xeris Biopharma ,Company Group Chairman ,Johnson Biotechnology ,Eli Lilly ,Worldwide Oncology Unit ,Imclone Systems ,Autolus Therapeutics ,Verastem Oncology ,North America ,